{"filing":{"accession_number":"0001420720-26-000014","cik":"0001420720","ticker":"IBIO","company_name":"iBio, Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-07-31","primary_document":"ibio-20260722x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072026000014/ibio-20260722x8k.htm"},"events":[{"id":23952,"run_id":21664,"accession_number":"0001420720-26-000014","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Dr. Molly Carr was appointed as Chief Medical Officer of iBio effective July 31, 2026. The appointment includes compensatory arrangements (base salary of $470,000, 40% target bonus, and a 430,000-share inducement stock option award) and is material to the clinical-stage biotech company as it strengthens clinical leadership during a critical phase of pipeline advancement into the clinic.","company_name":"iBio, Inc.","ticker":"IBIO","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24316,"accession_number":"0001420720-26-000014","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Dr. Molly Carr was appointed as Chief Medical Officer of iBio effective July 31, 2026. While the disclosure includes compensatory details (base salary of $470,000, 40% target bonus, and a 430,000-share inducement stock option award), the principal disclosed action is the appointment of a named executive officer to a C-suite position. The appointment is material to a clinical-stage biotech company advancing its pipeline, as reflected in the CEO's statement that her appointment \"is a critical step as we advance our obesity and cardiometabolic pipeline into the clinic.\"","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:33:31.307710+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24317,"accession_number":"0001420720-26-000014","item_number":"8.01","item_title":"Other Events.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Dr. Molly Carr as Chief Medical Officer of iBio, Inc., effective August 4, 2026. While the Item 8.01 section also mentions an inducement equity award (430,000 stock options), the principal disclosed action is the appointment itself—a senior executive leadership position at a clinical-stage biotechnology company. The press release emphasizes her 30+ years of clinical and biopharmaceutical experience and her role leading the company's global clinical strategy, medical affairs, and regulatory initiatives as the company advances its pipeline. This is material to investors as it reflects strengthening of clinical leadership during a critical phase of pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:33:31.307710+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24316,"accession_number":"0001420720-26-000014","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Dr. Molly Carr was appointed as Chief Medical Officer of iBio effective July 31, 2026. While the disclosure includes compensatory details (base salary of $470,000, 40% target bonus, and a 430,000-share inducement stock option award), the principal disclosed action is the appointment of a named executive officer to a C-suite position. The appointment is material to a clinical-stage biotech company advancing its pipeline, as reflected in the CEO's statement that her appointment \"is a critical step as we advance our obesity and cardiometabolic pipeline into the clinic.\"","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:33:31.307710+00:00","company_name":"iBio, Inc.","ticker":"IBIO","filing_date":"2026-08-04"},{"id":24317,"accession_number":"0001420720-26-000014","item_number":"8.01","item_title":"Other Events.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Dr. Molly Carr as Chief Medical Officer of iBio, Inc., effective August 4, 2026. While the Item 8.01 section also mentions an inducement equity award (430,000 stock options), the principal disclosed action is the appointment itself—a senior executive leadership position at a clinical-stage biotechnology company. The press release emphasizes her 30+ years of clinical and biopharmaceutical experience and her role leading the company's global clinical strategy, medical affairs, and regulatory initiatives as the company advances its pipeline. This is material to investors as it reflects strengthening of clinical leadership during a critical phase of pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:33:31.307710+00:00","company_name":"iBio, Inc.","ticker":"IBIO","filing_date":"2026-08-04"}]}